<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369938</url>
  </required_header>
  <id_info>
    <org_study_id>Ex-VAD</org_study_id>
    <nct_id>NCT03369938</nct_id>
  </id_info>
  <brief_title>Exercise Training in Patients With Left Ventricular Assist Device</brief_title>
  <acronym>Ex-VAD</acronym>
  <official_title>Exercise Training in Patients With Left Ventricular Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test whether 12 weeks of structured supervised exercise&#xD;
      training on top of usual care improves functional capacity in patients with end-stage heart&#xD;
      failure with continuous flow left ventricular assist device (LVAD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in maximal exercise capacity</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>cardiopulmonary exercise testing (CPET; peakVO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in ventilatory efficacy</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>cardiopulmonary exercise testing (CPET; VE/VCO2 slope)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in submaximal exercise tolerance</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>6-minute-walk distance (m), anaerobic threshold (VO2 at AT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in muscle strength</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>handgrip (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in body composition</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>% fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>patient-reported measure of quality of life for patients with heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Survey (SF-36)</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>patient-reported measure of health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>patient-reported measure of presence and severity of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in echocardiographic parameters of cardiac morphology and function at rest and during exercise</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>left ventricular ejection fraction (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in echocardiographic parameters of cardiac morphology and function at rest and during exercise</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>left ventricular end diastolic volume (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in echocardiographic parameters of cardiac morphology and function at rest and during exercise</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>left ventricular end diastolic diameters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in echocardiographic parameters of cardiac morphology and function at rest and during exercise</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>tricuspid annular plane systolic excursion (TAPSE; mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in markers of neuroendocrine activation</measure>
    <time_frame>after 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>NT-proBNP (ng/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in daily physical activity</measure>
    <time_frame>up to 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>physical activity diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in daily physical activity</measure>
    <time_frame>up to 12 weeks of treatment and 12 weeks of follow-up</time_frame>
    <description>accelerometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adherence to exercise training</measure>
    <time_frame>up to 12 weeks of treatment</time_frame>
    <description>accelerometry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>exercise training intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exercise training intervention</intervention_name>
    <description>structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)</description>
    <arm_group_label>exercise training intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic end-stage systolic heart failure&#xD;
&#xD;
          -  stable on left ventricular assist device, meaning&#xD;
&#xD;
               1. no major change in therapeutic regime within past 4 weeks: no new additional&#xD;
                  disease modifying drug (ACE inhibitor, ARB, sacubitril, beta-blocker), no change&#xD;
                  in disease modifying drug dosage more than 50% (excluded: diuretics), no&#xD;
                  initiation of a cardiac rehabilitation for a minimum of 4 weeks&#xD;
&#xD;
               2. post implantation ≥ 3 months&#xD;
&#xD;
               3. expected further period on the device for a minimum of 3 months after recruitment&#xD;
                  into the study&#xD;
&#xD;
          -  ability to complete the study in compliance with the protocol.&#xD;
&#xD;
          -  general ability of the patient to declare willingness to participate in the trial.&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute illness that does not allow exercise, including unstable heart failure, acute&#xD;
             myocarditis, acute pericarditis, stroke&#xD;
&#xD;
          -  untreated life-threatening cardiac arrhythmias&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  intracardiac thrombus&#xD;
&#xD;
          -  inability to perform cardiopulmonary exercise testing at least 1 minute at 20W&#xD;
&#xD;
          -  uncontrolled diabetes&#xD;
&#xD;
          -  uncontrolled kidney disease&#xD;
&#xD;
          -  recent embolism&#xD;
&#xD;
          -  concurrent, continuous, or intermittent dobutamine therapy&#xD;
&#xD;
          -  complex ventricular arrhythmia at rest or appearing with exertion&#xD;
&#xD;
          -  supine resting heart rate &gt; 100 beats per minute&#xD;
&#xD;
          -  severe pulmonary instability&#xD;
&#xD;
          -  hemodynamically relevant valvular disorders&#xD;
&#xD;
          -  significant change in cardiovascular medication within the previous 4 weeks (see&#xD;
             inclusion criteria)&#xD;
&#xD;
          -  severe anemia (hemoglobin &lt;8 g/dl), however patients with moderate anemia (hemoglobin&#xD;
             &lt;11 g/dl) may be recruited if clinically stable (investigator assessment)&#xD;
&#xD;
          -  clinically relevant musculoskeletal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin und Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München und Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80992</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://ex-vad.dzhk.de/</url>
    <description>Ex-VAD trial website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Univ.-Prof. Dr. med. Frank Edelmann</investigator_full_name>
    <investigator_title>Professor for Cardiovascular Prevention and Clinical Heart Failure Research</investigator_title>
  </responsible_party>
  <keyword>left ventricular assist device</keyword>
  <keyword>exercise training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

